Search Results - "PELAIA, G."

High-flow nasal oxygen therapy in intensive care and anaesthesia by Renda, T, Corrado, A, Iskandar, G, Pelaia, G, Abdalla, K, Navalesi, P

“…Oxygen therapy is first-line treatment for hypoxaemic acute respiratory failure (ARF). High-flow nasal oxygen therapy (HFNO) represents an alternative to…”
Get more information

Effects of benralizumab in patients with severe eosinophilic asthma (SEA): A plain language summary of the ANANKE study by Canonica, G W, Consani, L, Malerba, L, Pelaia, G, Vultaggio, A

“…This summary outlines the findings from the ANANKE study on the treatment of patients with severe eosinophilic asthma (SEA) with benralizumab. SEA is an…”
Get more information

Nitric oxide in upper airways inflammatory diseases by Maniscalco, M, Sofia, M, Pelaia, G

“…In the human respiratory tract, the main production sites of exhaled nitric oxide (NO) are the nose and paranasal sinuses. In the upper airways, NO has been…”
Get full text

Increased activation of p38 MAPK in COPD by Renda, T, Baraldo, S, Pelaia, G, Bazzan, E, Turato, G, Papi, A, Maestrelli, P, Maselli, R, Vatrella, A, Fabbri, L. M, Zuin, R, Marsico, S. A, Saetta, M

“…Inflammation, oxidative stress and apoptosis, which are involved in chronic obstructive pulmonary disease (COPD) pathogenesis, may activate the p38 subgroup of…”
Get full text

Effects of statins and farnesyl transferase inhibitors on ERK phosphorylation, apoptosis and cell viability in non-small lung cancer cells by Pelaia, G., Gallelli, L., Renda, T., Fratto, D., Falcone, D., Caraglia, M., Busceti, M. T., Terracciano, R., Vatrella, A., Maselli, R., Savino, R.

“…Objective 3‐hydroxy‐3‐methylglutaryl‐coenzyme A (HMG‐CoA) reductase inhibitors (statins) can affect post‐translational processes, thus being responsible for…”
Get full text

What drives inhaler prescription for asthma patients? Results from a real-life retrospective analysis by Lavorini, F., Bianco, A., Blasi, F., Braido, F., Corsico, A.G., Di Marco, F., Gentile, A., Paggiaro, P.L., Pegoraro, V., Pelaia, G., Rogliani, P., Santus, P., Scichilone, N., Soldi, A., Canonica, G.W.

“…The choice of inhaler device for asthma patients depends upon multiple attributes. We investigated factors that may drive general practitioners (GPs) and…”
Get full text

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review by Rogliani, Paola, Calzetta, Luigino, Braido, Fulvio, Cazzola, Mario, Clini, Enrico, Pelaia, Girolamo, Rossi, Andrea, Scichilone, Nicola, Di Marco, Fabiano

“…The aim of this study was to assess the current evidence for long-acting β -agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations…”
Get full text

Severe asthma and long-term Benralizumab effectiveness in real-life by Sposato, B, Scalese, M, Camiciottoli, G, Carpagnano, G E, Pelaia, C, Santus, P, Pelaia, G, Palmiero, G, Di Tomassi, M, Ronchi, M C, Cameli, P, Bargagli, E, Ciambellotti, L, Rizzello, S, Sglavo, R, Coppola, A, Lacerenza, L G, Gabriele, M, Radovanovic, D, Perrella, A, Ricci, A, Rogliani, P

“…Long-term efficacy of Benralizumab in real life is not clearly known. We assessed the long-term effectiveness persistence to anti-IL-5R treatment in a group of…”
Get more information

Italian real-life experience of omalizumab by Cazzola, M, Camiciottoli, G, Bonavia, M, Gulotta, C, Ravazzi, A, Alessandrini, A, Caiaffa, M.F, Berra, A, Schino, P, Di Napoli, P.L, Maselli, R, Pelaia, G, Bucchioni, E, Paggiaro, P.L, Macchia, L

“…Summary Omalizumab is a humanized murine monoclonal antibody directed toward a portion of the IgE indicated in Europe for the treatment of severe persistent…”
Get full text

Sirtuin 1 and Aging Theory for Chronic Obstructive Pulmonary Disease by Filippelli, Amelia, Pelaia, Girolamo, Manzo, V., Corbi, Graziamaria, Conti, V., Vatrella, Alessandro

“…Chronic Obstructive Pulmonary disease (COPD) is an inflammatory syndrome that represents an increasing health problem, especially in the elderly population…”
Get full text

P637: FRONTLINE THERAPY CLL WITHOUT 17P DEL/P53 ABERRATIONS: SYSTEMATIC REVIEW AND BAYESIAN NETWORK META‐ANALYSIS by Caridà, G., Ciliberto, D., Pelaia, G., Staropoli, N., Siciliano, M. A., Calandruccio, N. D., Toscano, R., Rossi, M.

Get full text

Influence of allergic status and nasal polyposis on long-term Benralizumab response in eosinophilic severe asthma by Sposato, B, Ricci, A, Camiciottoli, G, Carpagnano, G E, Pelaia, C, Santus, P, Pelaia, G, Palmiero, G, Di Tomassi, M, Ronchi, M C, Cameli, P, Bargagli, E, Ciambellotti, L, Rizzello, S, Sglavo, R, Coppola, A, Lacerenza, L G, Gabriele, M, Radovanovic, D, Perrella, A, Rogliani, P, Scalese, M

“…It is unclear whether Benralizumab effectiveness in severe eosinophilic asthma can be influenced by nasal polyposis (NP) or allergic status associations. We…”
Get more information

Early management of COPD: where are we now and where do we go from here? A Delphi consensus project by Di Marco, Fabiano, Balbo, Piero, de Blasio, Francesco, Cardaci, Vittorio, Crimi, Nunzio, Girbino, Giuseppe, Pelaia, Girolamo, Pirina, Pietro, Roversi, Pietro, Santus, Pierachille, Scichilone, Nicola, Vatrella, Alessandro, Pasqualetti, Patrizio, Carone, Mauro

“…There is a lack of consensus on the most appropriate early diagnostic strategy, criteria for early access to treatment and follow-up approach for patients with…”
Get full text

Effects of simvastatin and rosuvastatin on RAS protein, matrix metalloproteinases and NF-κB in lung cancer and in normal pulmonary tissues by Falcone, D., Gallelli, L., Di Virgilio, A., Tucci, L., Scaramuzzino, M., Terracciano, R., Pelaia, G., Savino, R.

“…Objectives In this study, we have evaluated effects of 24‐hour treatments with simvastatin or rosuvastatin on RAS protein, NF‐κB and MMP expression in LC…”
Get full text

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study by Senna, Gianenrico, Aliani, Maria, Altieri, Elena, Bracciale, Pietro, Brussino, Luisa, Caiaffa, Maria Filomena, Cameli, Paolo, Canonica, Giorgio Walter, Caruso, Cristiano, D'Amato, Maria, De Michele, Fausto, Del Giacco, Stefano, Di Marco, Fabiano, Menzella, Francesco, Pelaia, Girolamo, Rogliani, Paola, Romagnoli, Micaela, Schino, Pietro, Schroeder, Jan Walter, Vultaggio, Alessandra, Rizzoli, Sara, Zullo, Alessandro, Boarino, Silvia, Palmisano, Marilena, Rossi, Alessandra, Vitiello, Gianfranco, Centanni, Stefano

“…Purpose: Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count…”
Get full text

Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases by Pelaia, G, Vatrella, A, Cuda, G, Maselli, R, Marsico, S.A

“…Although corticosteroids have been used for a long time as a very effective therapy of airway inflammatory diseases such as asthma, only recently the molecular…”
Get full text

Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis by Sposato, B., Scalese, M., Camiciottoli, G., Carpagnano, G.E., Pelaia, C., Santus, P., Maniscalco, M., Corsico, A., Grosso, A., Baglioni, S., Murgia, N., Folletti, I., Pelaia, G., Masieri, S., Cavaliere, C., Musarra, A., Bargagli, E., Ricci, A., Latorre, M., Rogliani, P., Paggiaro, P.

Get full text

Omalizumab decreases exacerbation frequency, oral intake of corticosteroids and peripheral blood eosinophils in atopic patients with uncontrolled asthma by Pelaia, G, Gallelli, L, Romeo, P, Renda, T, Busceti, M T, Proietto, A, Grembiale, R D, Marsico, S A, Maselli, R, Vatrella, A

“…Omalizumab is a humanized monoclonal anti-IgE antibody approved in 2005 by the European Medicine Agency (EMA) for the treatment of severe persistent allergic…”
Get full text

Effects of budesonide on P38 MAPK activation, apoptosis and IL-8 secretion, induced by TNF-alpha and Haemophilus influenzae in human bronchial epithelial cells by Gallelli, L, Pelaia, G, Fratto, D, Muto, V, Falcone, D, Vatrella, A, Curto, L S, Renda, T, Busceti, M T, Liberto, M C, Savino, R, Cazzola, M, Marsico, S A, Maselli, R

“…Non-typeable Haemophilus influenzae (NTHi) is one of the most frequently involved pathogens in bacterial exacerbations of chronic obstructive pulmonary disease…”
Get more information

Neuropeptide expression in the airways of COPD patients and smokers with normal lung function by Vatrella, A, Montagnani, S, Calabrese, C, Parrella, R, Pelaia, G, Biscione, G L, Corcione, N, Marsico, S A, Guerra, G

“…Neurogenic mechanisms seem to play a role in the pathogenesis of chronic obstructive pulmonary disease (COPD), as suggested by a number of in vitro data…”
Get more information